• Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2

  NCT06742931

  RecruitingInterventionalNot ApplicableUpdated Nov 28, 2025
• STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation

  NCT03184805

  TerminatedInterventionalNot ApplicableUpdated May 22, 2018
• Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)

  NCT07587099

  RecruitingInterventionalNot ApplicableUpdated Aug 17, 2026
• Drug Coated Balloon vs. Drug-eluting Stent in Patients With Coronary Artery Disease

  NCT07442500

  Not yet recruitingObservationalUpdated Mar 2, 2026
• A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic Patients

  NCT00493779

  CompletedInterventionalPhase 4Updated Aug 10, 2010
• Drug Coated Balloon Compared to Bare Metal Stent for de Novo Coronary Artery Lesions

  NCT02456402

  CompletedInterventionalNot ApplicableUpdated Apr 3, 2019

ClinicalTrials.gov ID

NCT07398001

Lead Sponsor

Ulsan University HospitalOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

1,042Estimated

Last Update Posted

Feb 9, 2026Actual

Start Date

Feb 12, 2026Estimated

Primary Completion Date

Feb 11, 2028Estimated

Completion Date

Jul 31, 2030Estimated

Official Title

Discontinuation of Antiplatelet Therapy After Drug-Coated Balloon Treatment

Brief Summary

The goal of this clinical trial is to evaluate the benefits and risks of discontinuing antiplatelet therapy on clinical outcomes in patients who previously underwent coronary intervention using a drug-coated balloon.

The main questions it aims to answer are:

Does stopping antiplatelet therapy after 12 months affect the risk of net adverse clinical events? Does stopping antiplatelet therapy reduce the risk of bleeding compared with continuing treatment?

Researchers will compare patients who discontinue antiplatelet therapy with patients who continue antiplatelet therapy to determine the impact on clinical outcomes during follow-up.

Participants will:

Be randomly assigned to either discontinue or continue antiplatelet therapy Receive routine clinical follow-up through clinic visits or telephone contacts Be monitored for cardiovascular events and bleeding outcomes over time

Detailed Description

Coronary artery disease is a major cause of morbidity and mortality worldwide. Percutaneous coronary intervention is widely used for the treatment of coronary artery disease, traditionally involving implantation of drug-eluting stents. Although contemporary drug-eluting stents have improved safety and efficacy compared with earlier stent technologies, permanent metallic implants remain associated with long-term considerations, including restenosis, stent thrombosis, and the need for prolonged antiplatelet therapy.

Drug-coated balloon therapy represents an alternative revascularization strategy that delivers an antiproliferative drug to the coronary vessel wall without implantation of a permanent scaffold. This "leave-nothing-behind" approach has been adopted in specific clinical settings and has been increasingly applied in selected coronary lesions. The absence of a permanent implant may offer potential advantages with respect to long-term vessel healing and antiplatelet therapy management.

Bleeding complications after coronary intervention are clinically relevant and have been associated with adverse outcomes. Decisions regarding the duration of antiplatelet therapy require careful consideration of both ischemic and bleeding risks. While shorter durations of antiplatelet therapy have been explored following contemporary coronary interventions, optimal long-term antiplatelet strategies after drug-coated balloon-based procedures remain incompletely defined.

Limited data are available regarding the clinical outcomes associated with discontinuation of antiplatelet therapy beyond 12 months in patients who have undergone initial percutaneous coronary intervention using drug-coated balloon treatment and have remained clinically stable. As a result, uncertainty persists regarding the balance of potential benefits and risks of long-term antiplatelet therapy in this population.

This prospective, randomized, multicenter study is designed to compare clinical outcomes between patients who discontinue antiplatelet therapy and those who continue antiplatelet therapy after 12 months following drug-coated balloon-based percutaneous coronary intervention. The study aims to provide additional evidence to inform clinical decision-making regarding antiplatelet therapy management in patients treated with drug-coated balloons.

• Percutaneous Coronary Intervention
• Antiplatelet Therapy
• Drug-coated Balloon

• Stop Antiplatelet
• Continue Antiplatelet

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Adults aged 19 years or older who are able to understand the risks, benefits, and treatment alternatives of the study and who provide written informed consent voluntarily.
2. Patients who underwent drug-coated balloon treatment at least 12 months prior to enrollment.
3. Patients who have not experienced major adverse cardiovascular events, including myocardial infarction, stroke, or target vessel revascularization, since the index DCB treatment.
4. Patients who have not experienced major bleeding since the index DCB treatment.
5. Patients who are receiving antiplatelet therapy at the time of enrollment.

Exclusion Criteria:

1. Patients with concomitant vascular disease requiring long-term antiplatelet therapy.
2. Patients with non-cardiac comorbid conditions that, in the judgment of the investigator, are associated with a life expectancy of less than 1 year or may result in poor compliance with the study protocol.
3. Patients who are participating in another drug or coronary device clinical study at the time of enrollment.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Ulsan University HospitalOTHER

hermartha@hanmail.net+82-10-6375-3863

circleabc@naver.com

gelly9@naver.com

drone80@hanmail.net

scb77@daum.net

sesim1989@gmail.com+82-10-6319-4025